Department of Pediatrics, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
Department of Pediatrics, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
J Formos Med Assoc. 2019 Jan;118(1 Pt 2):332-340. doi: 10.1016/j.jfma.2018.05.015. Epub 2018 Jun 11.
Taiwan Pediatric Oncology Group (TPOG) initiated two consecutive protocols for treating pediatric patients with rhabdomyosarcoma since 1995. However, the results have not been analyzed and reported yet. The aim of this study is to investigate the treatment results of these two protocols in our hospital and to assess whether the results are comparable to other large-scaled studies.
Treatment of pediatric patients with rhabdomyosarcoma according to TPOG protocols at National Taiwan University Hospital began in 1995. Between 1995 and 2006, patients were treated by TPOG RMS 95 protocol, which was based on IRS-III/IV. After 2007, patients were treated by TPOG RMS 2007 protocol which was adapted from IRS-V study. The clinical data of patients were obtained retrospectively by reviewing medical records. The date of the latest follow-up was December 31, 2016.
Thirty-seven patients were enrolled in this study. The 5-year overall survival (OS) and event-free survival rates of them were 54.7 ± 8.8% and 48.5 ± 8.6%, respectively. The 5-year OS rates for patients treated by TPOG RMS 95 and TPOG RMS 2007 protocols were 55.0 ± 11.1% and 55.9 ± 14.0%, respectively. Age at diagnosis of less than ten years old and receiving operation with gross total or subtotal tumor resection were identified as independent prognostic factors that predicted better outcomes in the multivariate analysis.
The clinical outcomes of pediatric patients with rhabdomyosarcoma in Taiwan improved dramatically after incorporating two consecutive protocols from TPOG. In addition, the treatment results of these two protocols were comparable to large-scale studies of other countries.
台湾小儿肿瘤团体（TPOG）自 1995 年以来发起了两项连续的横纹肌肉瘤患儿治疗方案。然而，这些结果尚未进行分析和报告。本研究旨在探讨我院采用这两个方案治疗横纹肌肉瘤患儿的疗效，并评估其结果是否与其他大规模研究相当。
我院自 1995 年起依据 TPOG 方案治疗横纹肌肉瘤患儿。1995 年至 2006 年，采用 TPOG RMS 95 方案治疗，该方案基于 IRS-III/IV。2007 年以后，采用 TPOG RMS 2007 方案治疗，该方案改编自 IRS-V 研究。通过查阅病历回顾性收集患者的临床资料。截至 2016 年 12 月 31 日，记录患者的最后随访日期。
本研究共纳入 37 例患者。患者的 5 年总生存率（OS）和无事件生存率分别为 54.7±8.8%和 48.5±8.6%。接受 TPOG RMS 95 和 TPOG RMS 2007 方案治疗的患者的 5 年 OS 率分别为 55.0±11.1%和 55.9±14.0%。多因素分析显示，诊断时年龄<10 岁和接受手术且肿瘤肉眼全切除或次全切除是预测患者预后更好的独立预后因素。
台湾采用 TPOG 连续两项方案治疗横纹肌肉瘤患儿后，临床疗效显著改善。此外，这两个方案的治疗结果与其他国家的大规模研究相当。
